NBS SEEKING ALPHA ARTICLE //NeoStem: The Best Upside In An

New Post Public Reply Private Reply Replies (1) Message Board

Oct 9, 2012 at 9:19 AM

[b]NBS >> SEEKING ALPHA ARTICLE //NeoStem: The Best Upside In An Innovating Space[/b]
October 7, 2012
by: Henry Kawabe
| about: NBS, includes: BAX, CUR, OSIR, STEM
Disclosure: I am long NBS. (More...)

There is one change in the medical arena that investors are going to have to embrace, or at least accept: cell
therapy. In 2012, some of the best performing stocks in biotechnology have been in cell therapy. Already, we have
crossed a number of barriers. We've seen the first approved product with a cell therapy as a main component: Osiris
Therapeutics' (OSIR) Prochymal. Shares of Neuralstem (CUR) have nearly doubled in the last month alone as its
cell therapy showed a benefit of motor function in paralysis, a benefit never before reached. StemCells (STEM) has
also been a big-time performer following data that its cell therapy restored memory and enhanced synaptic function in
Alzheimer's disease. And if that's not enough, Baxter (BAX) recently reached endpoints never before conquered,
increasing exercise capacity and reducing angina due to chronic myocardial ischemia. The takeaway: It has been an
incredible year, and with such breakthrough data, it is only getting better.
In biotechnology, we've seen a number of novel therapeutics with crucial data as we inch closer to curing and
effectively treating life-threatening diseases. Cell therapy has been at the forefront of this movement - it has provided
proof of concept curing some of today's most deadly degenerative diseases - but is still in its early stages of
development.
With only one approved product that has a cell therapy as its main component, the potential for new treatments and
the outlook for those treatments is at an all-time high. The valuation for companies in this space is particularly
attractive, perhaps greater than in any other industry within biotechnology. The reason for attractive valuations is due
to skepticism among some who have yet to embrace the benefits of cell therapy. These people may believe that we'll
never see a large diversified product line of cell therapies, or that regulators will never accept the benefits of cell
therapy. However, this argument doesn't make sense, because countries around the globe are spending more on cell
therapies than at any point in our history. There is a significant cost benefit to cell therapies, not to mention
efficiency, that will replace inefficient therapeutics that are being used to treat degenerative diseases. For this reason,
we will see approvals in the cell therapy arena. We will see cheaper and more efficient therapies to treat diseases
that have limited or no current treatments, and this will occur because of clinical results, and over a period of several
years.
So how should investors play the growth of this space? Investors could invest in a company such as CUR or STEM.
But these companies are still early in the clinical process, and are more likely to benefit from the approvals of other
cell therapies; they will trade with far less upside than later-stage companies with similar valuations. You could invest
in the first approved cell therapy and OSIR. However, its product Prochymal is more of a "door opener" and not a
large revenue-producing product. The difficult aspect to finding a good investment is that there are a lot of cell therapy
companies with a lack of diversification-or only one significant product of growth-and we must assume that, despite
their promise, it may take a few years for cell therapies to gain full acceptance and reach full potential. So after
searching throughout the entire space, and reading 100s of reviews, business plans, and assessing market potential,
I feel confident that the best play in the space is NeoStem Inc. (NBS).
NeoStem
NeoStem is a $105 million market capitalization company with expertise and a presence that stretches far beyond
the norm of cell therapy and developmental-stage companies. The company operates in several segments, with a
diversified presence in the space, and has been a great investment in 2012, with an 81% return over the last six
months. The stock has returned a gain of more than 10% over the last month, but is now trading very close to its
support, therefore indicating short-term upside. Unlike most biotechnology companies of its size, NeoStem has

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rise Treatment Center Launches in Vegas for Teens

Las Vegas Debuts Rise Adolescent Treatment Center Imagine being a parent in Las Vegas, staring at the daunting task of finding genuine help for your teenage kid just entering those rebellious years. The choices usually feel sparse and lacking. But on August 13, 2026, a shimmer of hope illuminated the landscape with the opening of Rise Adolescent Treatment Center. It’s a...

Dr. David Lifschutz Honored for Psychiatry Innovation

Recognizing a Legacy in Mental Wellness Under the glare of recognition's spotlight, Dr. David H. Lifschutz steps into an exclusive circle of elite professionals. He's been acknowledged as a Pinnacle Lifetime Member by The Inner Circle for his remarkable contributions to psychiatry and mental health care. This ain't just any pat on the back. It's a badge of honor stitched...

Starr Conspiracy Unveils AI Tool for B2B Tech Firms

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...

NSF Backs New Space Projects: Cooling & Drug Delivery

You know, every time we think we're at the edge of current science, space reminds us how little we actually know. From the International Space Station up there in low Earth orbit, fresh experiments are kicking off to change what we understand about electronics cooling and drug delivery. It's a classic scenario of reaching for the stars to help us out back here on Earth....

Unicycive's Legal Turmoil: Opportunity for Investor Action

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

Brands Must Choose: Cost or Value Leadership?

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

illycaffè's B Corp™ Recertification Reflects Bold Commitment

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

Subaru, Motorq Offer Hardware-Free Fleet Telematics Insights

An Unplugged Move in Fleet Management There's something brewing between Motorq and Subaru that could shake up fleet operations in ways most haven't thought possible yet. We’re talking about cutting those pesky hardware cords and diving straight into a future that's software-driven—and hey, we're all here for it. Direct, Data-Driven Leadership Imagine you're a fleet...

Lincoln Educational Services Faces Securities Fraud Suit

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

New Podcast by Paralyzed Veterans of America Offers Unique Insights

Empowering Veterans Through Storytelling Some stories don't just rattle around in your headphones—they stick with you. The 'Voices of PVA' podcast, launched by Paralyzed Veterans of America, aims to do exactly that. It's not just a podcast; it's a platform where voices of veterans and people with spinal cord injuries like MS and ALS aren't just heard, they're amplified....